-

Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 2:20 p.m. EST.

A live webcast of the presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 30 days on Karuna’s website following the conference.

About Karuna
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

Contacts

Investors:
Alexis Smith
518-338-8990
asmith@karunatx.com

Media:
Bob Josefsberg
646-734-3584
bjosefsberg@karunatx.com

KARUNA THERAPEUTICS

NASDAQ:KRTX
Details
Headquarters: Boston, MA USA
CEO: Bill Meury
Employees: 210
Organization: PUB

Release Versions
$Cashtags

Contacts

Investors:
Alexis Smith
518-338-8990
asmith@karunatx.com

Media:
Bob Josefsberg
646-734-3584
bjosefsberg@karunatx.com

More News From KARUNA THERAPEUTICS

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update. “2023 was a landmark year for Karuna, marked by the FDA acceptance of our NDA for KarXT for the treatment of schizophrenia in adults, with...

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”) today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and Karuna Boards of Directors. Ka...

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that results from the Phase 3 EMERGENT-2 trial of KarXT (xanomeline-trospium) in adults with schizophrenia were published in The Lancet. The manuscript shares KarXT data showcasing a clinically meaningful and statistically significant reduction in positive a...
Back to Newsroom